Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000403878 | SCV000338252 | uncertain significance | not provided | 2015-12-17 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001089130 | SCV001098990 | likely benign | Glycogen storage disease, type II | 2024-01-04 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000403878 | SCV001758451 | likely benign | not provided | 2020-09-11 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001089130 | SCV001810601 | uncertain significance | Glycogen storage disease, type II | 2021-07-22 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002392802 | SCV002701757 | likely benign | Cardiovascular phenotype | 2020-08-17 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Natera, |
RCV001089130 | SCV002092026 | likely benign | Glycogen storage disease, type II | 2020-11-17 | no assertion criteria provided | clinical testing |